Rinvoq (upadacitinib)

• Rheumatoid arthritis: adults with moderately to severely active rheumatoid arthritis after one or more TNF blockers (a type of biologic medicine) did not work well enough or could not be tolerated.
• Psoriatic arthritis: adults and children 2 years and older with active psoriatic arthritis after one or more TNF blockers did not work well enough or could not be tolerated.
• Atopic dermatitis (eczema): adults and children 12 years and older with hard-to-treat, moderate to severe atopic dermatitis that is not well controlled with other medicines taken by mouth or shot, including biologics, or when those medicines are not a good choice.
• Ulcerative colitis: adults with moderately to severely active ulcerative colitis after one or more TNF blockers did not work well enough or could not be tolerated (or, if TNF blockers are not a good choice, after at least one other approved systemic treatment).
• Crohn's disease: adults with moderately to severely active Crohn's disease after one or more TNF blockers did not work well enough or could not be tolerated (or, if TNF blockers are not a good choice, after at least one other approved systemic treatment).
• Ankylosing spondylitis: adults with active ankylosing spondylitis (arthritis of the spine) after one or more TNF blockers did not work well enough or could not be tolerated.
• Non-radiographic axial spondyloarthritis: adults with active non-radiographic axial spondyloarthritis (spine arthritis that does not show on X-rays) with signs of inflammation, after TNF blocker treatment did not work well enough or could not be tolerated.
• Polyarticular juvenile idiopathic arthritis (pJIA): children 2 years and older with active pJIA (arthritis in many joints that starts in childhood) after one or more TNF blockers did not work well enough or could not be tolerated.
• Giant cell arteritis: adults with giant cell arteritis (swelling of large blood vessels, often in the head).

A prescription is required. Your prescriber decides whether Rinvoq is right for you.

Tablet or capsule by mouth, given by you. We ship it to your door.

Storage: Store the tablets between 36°F and 77°F in the original bottle to protect them from moisture. Rinvoq LQ liquid is stored between 36°F and 86°F and thrown away 60 days after the bottle is opened.

Before the first dose, your prescriber may ask for:

• a test for tuberculosis (TB)
• a blood test for viral hepatitis, such as hepatitis B and C
• a complete blood count (CBC)
• liver blood tests
• a pregnancy check for anyone who could become pregnant
• bringing your vaccines up to date, including the shingles vaccine

Important safety information: This medicine has a boxed warning about serious infections (including TB), death, certain cancers (including lymphoma), major heart problems such as heart attack and stroke, and blood clots. People who smoke now or smoked in the past have a higher risk of cancer and heart problems.

Read the Medication Guide and the full Rinvoq prescribing information, and ask your prescriber or our pharmacists about side effects. Our pharmacists are on call 24 hours a day.

Health plans often require prior authorization for Rinvoq. Our intake team checks your coverage and works with your prescriber’s office on the paperwork before your first delivery.

The manufacturer runs a support program, Rinvoq Complete, that may help eligible patients with costs and access.

Offices can call (844) 671-2600 or fax a referral to (844) 671-2601. Use the Rheumatology Referral Form (PDF).

The manufacturer also publishes Rinvoq Complete enrollment and prescription forms.